intraperitoneally with PAK wildtype at $3LD_{50}$. Mice were monitored on a hourly basis between 16 and 48 hours. As seen in Figure 9, percent survival was dose dependent within the range of pilin protein amounts tested.

After page 15, please add pages 1-9 of the sequence listing attached hereto as Exhibit A.

IN THE CLAIMS

Please add Claim 20 as follows:

Claim 20 (newly added) A method of treating or preventing infection by *Pseudomonas aeruginosa* comprising administering a pharmaceutically acceptable amount of an isolated pilin peptide having the amino acid sequence set forth in SEQ ID Nos. 4, 6, 8, or 10.

Please ~~cancel~~ Claims 1-19 without prejudice or disclaimer.

REMARKS

Applicants respectfully request that the Preliminary Amendment be entered prior to the examination of the above-identified application.

Applicants submit that the Preliminary Amendment makes changes to the Specification for priority purposes and in accordance with those changes made to U.S. Patent Application No. 09/329,884. Claim 20 has been newly added for reconsideration upon examination.

Accordingly, Applicants respectfully request early and favorable consideration of the present application.

Respectfully submitted,

Robert M. Barrett (Reg. No. 30,142)
BELL, BOYD & LLOYD LLC
P.O. Box 1135
Chicago, Illinois 60690-1135
(312) 807-4204
ATTORNEY FOR APPLICANTS

384858v1/D